ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market

About this update from Abl Diagnostics Sa

WOIPPY, France, November 14, 2025 --( BUSINESS WIRE )--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio Scientific (Euronext Growth Paris: ALERS, ISIN FR0013240934), a leading in vitro diagnostics company, for the commercialization of its VELA product line within a defined segment of the French public hospital market. Effectively, this agreement aims to enhance access to ABL Diagnostics’ next-generation sequencing (NGS) and viral genotyping solutions, while ensuring optimal local service for end users. A targeted collaboration to enhance customer service Under the agreement: This differentiated approach enables optimized market coverage while maintaining a high standard of service for healthcare professionals and patients. A logical continuation with a long-standing partner Eurobio Scientific has historically distributed the VELA product line in France and several European countries, prior to its integration into ABL Diagnostics’ portfolio. Its subsidiary, Eurobio Scientific UK, currently distributes both the VELA and DeepChek® platforms as complementary technological and scientific solutions designed to meet diverse clinical needs and market segments. In this context, it is strategically sound to continue this collaboration on selected key accounts in France, leveraging Eurobio’s experience and ensuring a seamless transition for end users. A consistent European expansion strategy This agreement follows several recent strategic announcements by ABL Diagnostics: Advanced technology for hospital virology The VELA product line, distributed by ABL Diagnostics, includes CE-IVD and RUO solutions for NGS-based molecular diagnostics, with applications in virology, particularly for HIV, HCV, and CMV genotyping. These products enable precise detection of viral mutations, essential for personalized therapeutic management. "This partnership with Eurobio Scientific is fully aligned with our growth strategy in the public hospital market. It allows us to optimize commercial coverage while ensuring proximity service and high-level technical support," said Chalom Sayada, CEO of ABL Diagnostics. The detailed terms of the agreement remain confidential. About ABL Diagnostics (ABLD) ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers: ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion. ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. An expanding portfolio of microbiology products: Integrated Solutions: ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology. View source version on businesswire.com: https://www.businesswire.com/news/home/20251113822479/en/ Contacts ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50 Email : [email protected] https://www.abldiagnostics.com/

View stock analysis, news, and events for Abl Diagnostics Sa